Journal
EBIOMEDICINE
Volume 79, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2022.103986
Keywords
COVID-19; SARS-CoV-2; Omicron variant; Neutralizing antibody; Surrogate neutralizing antibody test; Spike protein receptor binding domain; Beta variant; Delta variant; mRNA vaccine; Inactivated vaccine
Funding
- Health and Medical Research Fund
Ask authors/readers for more resources
The study showed that in recovered COVID-19 patients, recipients of the BNT162b2 vaccine had significantly higher serum Omicron neutralizing antibody titers compared to non-vaccinated individuals. Additionally, receiving two doses of CoronaVac was more effective in inducing detectable serum Omicron antibodies than one dose.
Background SARS-CoV-2 Omicron variant evades immunity from past infection or vaccination and is associated with a greater risk of reinfection among recovered COVID-19 patients. We assessed the serum neutralizing antibody (NAb) activity against Omicron variant (Omicron NAb) among recovered COVID-19 patients with or without vaccination. Methods In this prospective cohort study with 135 recovered COVID-19 patients, we determined the serum NAb titers against ancestral virus or variants using a live virus NAb assay. We used the receiver operating characteristic analysis to determine the optimal cutoff for a commercially-available surrogate NAb assay. Findings Among recovered COVID-19 patients, the serum live virus geometric mean Omicron NAb titer was statistically significantly higher among BNT162b2 recipients compared to non-vaccinated individuals (85.4 vs 5.6, P < 0.0001). The Omicron seropositive rates in live virus NAb test (NAb titer >= 10) were statistically significantly higher among BNT162b2 (90.6% [29/32];P < 0.0001) or CoronaVac (36.7% [11/30]; P = 0.0115) recipients when compared with non-vaccinated individuals (12.3% [9/73]). Subgroup analysis of CoronaVac recipients showed that the Omicron seropositive rates were higher among individuals with two doses than those with one dose (85.7% vs 21.7%; P = 0.0045). For the surrogate NAb assay, a cutoff of 109.1 AU/ml, which is 7.3-fold higher than the manufacturer's recommended cutoff, could achieve a sensitivity and specificity of 89.5% and 89.8%, respectively, in detecting Omicron NAb. Interpretation Among individuals with prior COVID-19, one dose of BNT162b2 or two doses of CoronaVac could induce detectable serum Omicron NAb. Our result would be particularly important for guiding vaccine policies in countries with COVID-19 vaccine shortage. Funding Health and Medical Research Fund, Richard and Carol Yu, Michael Tong (see acknowledgments for full list). Copyright (C) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available